JOHN TRIEU: Open Payments
NPI 1528478112 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,511 in 105 payments from 8 companies in 2025. Trend: 2023 $2,000 · 2024 $2,113 · 2025 $2,511
Food & beverage: $2,402Education: $109
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 24 | $553 |
| E.R. Squibb & Sons, L.L.C. | 16 | $529 |
| Teva Pharmaceuticals USA, Inc. | 18 | $473 |
| Otsuka America Pharmaceutical, Inc. | 19 | $359 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $277 |
| Janssen Pharmaceuticals, Inc | 9 | $179 |
| Neurocrine BioSciences, Inc. | 3 | $78 |
| Lundbeck LLC | 3 | $63 |
Products named: ARISTADA, COBENFY, UZEDY, CAPLYTA, ABILIFY ASIMTUFII, INVEGA SUSTENNA, REXULTI, INGREZZA.
Industry payments across CA — which companies pay providers there.
